Mutant Wilms tumor 1 (WT1) mRNA with premature termination codons in acute myeloid leukemia (AML) is sensitive to nonsense-mediated RNA decay (NMD)

Leukemia

Volumn 24, Issue 3, 2010, Pages 660-663

  Abbas, S ^a   Erpelinck Verschueren, C A J ^a   Goudswaard, C S ^a   Lowenberg B ^a   Valk, P J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MESSENGER RNA; RAS PROTEIN; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; FRAMESHIFT MUTATION; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; KARYOTYPE; LETTER; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON;

EID: 77949423045     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.265     Document Type: Letter

References (8)

1. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868-876.
2. King-Underwood L, Pritchard-Jones K. Wilms tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 1998; 91: 2961-2968.
3. Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007; 21: 550-551.
4. Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K, et al. Wilms tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 2008; 26: 4595-4602.
5. Virappane P, Gale R, Hills R, Kakkas I, Summers K, Stevens J, et al. Mutation of the Wilms tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429-5435.
6. Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSG). Blood 2009; 113: 4505-4511.
7. Kuzmiak HA, Maquat LE. Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges. Trends Mol Med 2006; 12: 306-316.
8. Wouters BJ, Jorda MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, Tielemans D, et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 2007; 110: 3706-3714.